Controlled release metformin compositions

a composition and metformin technology, applied in the field of oral dosage, can solve the problems of no fixed dosage regimen, little research in the field of controlled or sustained release compositions that employ antihyperglycemic drugs, etc., and achieve the effect of effective control of blood glucose levels

US20060008523A1Inactive Publication Date: 2006-01-12ANDRX
79 Cites 14 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
Publication Date
2006-01-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
Need to check novelty before this filing date? Find Prior Art

Description

BACKGROUND OF THE INVENTION

[0001] The present invention relates to controlled release unit dose formulations containing an antihyperglycemic drug. More specifically, the present invention relates to an oral dosage form comprising a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride or the metformin salts described in U.S. Pat. Nos. 3,957,853 and 4,080,472 which are incorporated herein by reference.

[0002] In the prior art, many techniques have been used to provide controlled and extended-release pharmaceutical dosage forms in order to maintain therapeutic serum levels of medicaments and to minimize the effects of missed doses of drugs caused by a lack of patient compliance.

[0003] In the prior art are extended release tablets which have an osmotically active drug core surrounded by a semipermeable membrane. These tablets function by allowing a fluid such as gastric or intestinal fluid to permeate the coating membran...

Examples

example 1

[0117] A controlled release tablet containing 500 mg of metformin HCl and having the following formula is prepared as follows:

[0118] I. Core

IngredientsAmount (mg / tab)Metformin HCl500.0Povidone3, USP36.0Sodium Lauryl Sulfate25.8Magnesium Stearate2.8

3approximate molecular weight = 1,000,000; dynamic viscosity (10% w / v solution at 20° C.) = 300-700 m Pa S.

[0119] (a) Granulation

[0120] The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70° C.; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml / min.

[0121] Once the binding solution is depleted, the granules are dried in the granula...

example 2

[0130] A controlled release tablet containing 850 mg of metformin HCl and having the following formula is prepared as follows:

[0131] I. Core

IngredientsAmount (mg / tab)Metformin HCl850.0Povidone3, USP61.1Sodium Lauryl Sulfate43.9Magnesium Stearate4.8

3approximate molecular weight = 1,000,000; dynamic viscosity (10% w / v solution at 20° C.) = 300-700 m Pa s.

[0132] (a) Granulation

[0133] The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70° C.; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml / min.

[0134] Once the binding solution is depleted, the granules are dried in the granula...

example 3

[0143] A controlled release tablet containing 1000 mg of metformin HCl and having the following formula is prepared as follows:

[0144] I. Core

IngredientsAmount (mg / tablet)Metformin HCl1000.0Povidone3, USP71.9Sodium Lauryl Sulfate51.7Magnesium Stearate5.6

3approximate molecular weight = 1,000,000; dynamic viscosity (10% w / v solution at 20° C.) = 300-700 m Pa s.

[0145] (a) Granulation

[0146] The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70° C.; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml / min.

[0147] Once the binding solution is depleted, the granules are dried in the granulator u...